Enovis (NYSE:ENOV) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Enovis (NYSE:ENOV) posted its quarterly earnings data on Thursday. The company reported $0.88 EPS for the quarter, beating the consensus estimate of $0.77 by $0.11, FiscalAI reports. The firm had revenue of $558.73 million during the quarter, compared to analyst estimates of $557.12 million. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. The company’s revenue for the quarter was up 1.8% on a year-over-year basis. During the same quarter last year, the business posted $0.75 EPS.

Here are the key takeaways from Enovis’ conference call:

• Enovis delivered 5% organic sales growth in Q3, led by 6% growth in Recon; P&R grew 3%. Adjusted EPS rose 17% to $0.88, while adjusted EBITDA margin expanded 120 basis points to 18.5%.
• The company raised its adjusted EBITDA outlook to $428 million–$438 million and adjusted EPS outlook to $3.58–$3.79, while maintaining expected organic growth of about 5%. It also reaffirmed its goal of greater than 25% free-cash-flow conversion in 2026.
• Management described markets as volatile, citing choppy U.S. hip and knee demand, challenging Western European conditions, and Middle East conflict that reduced total company growth by about 40 basis points. Inflation in raw materials, freight and distribution also pressured costs, partly offset by tariff refunds.
• Enovis expects to close its eCential Robotics acquisition by year-end and is investing in talent and technology ahead of integration. Management expects to bring a knee robot to market within two years, with shoulder to follow, and said customer feedback has been encouraging.
• The board authorized a $200 million share repurchase program, which management said it will use opportunistically while targeting leverage of 2.5–3.5 times. Net leverage was 2.9 times at quarter-end and is expected to rise about half a turn after the eCential deal closes.

Enovis Price Performance

ENOV stock traded down $1.46 during mid-day trading on Friday, reaching $27.16. 2,304,734 shares of the company traded hands, compared to its average volume of 1,786,351. The company has a fifty day moving average price of $19.91 and a 200-day moving average price of $23.09. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.15 and a quick ratio of 1.00. The company has a market capitalization of $1.57 billion, a P/E ratio of 8.04 and a beta of 1.31. Enovis has a 52-week low of $16.70 and a 52-week high of $32.41.

Insider Buying and Selling at Enovis

In other Enovis news, insider Oliver Engert acquired 5,140 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The stock was bought at an average price of $19.46 per share, with a total value of $100,024.40. Following the completion of the purchase, the insider owned 61,238 shares of the company’s stock, valued at approximately $1,191,691.48. This represents a 9.16% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Damien Mcdonald bought 13,035 shares of Enovis stock in a transaction that occurred on Friday, September 4th. The shares were acquired at an average price of $19.15 per share, with a total value of $249,620.25. Following the completion of the transaction, the chief executive officer owned 247,077 shares of the company’s stock, valued at $4,731,524.55. This represents a 5.57% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders bought 23,293 shares of company stock worth $449,599. Insiders own 2.90% of the company’s stock.

Trending Headlines about Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q3 adjusted earnings were $0.88 per share, beating estimates of about $0.77 and topping $0.75 a year earlier. Revenue of $558.7 million slightly exceeded forecasts and grew 1.8% year over year. Enovis Q3 2026 results
• Positive Sentiment: Enovis raised its 2026 EPS guidance to $3.58–$3.79, signaling improved earnings expectations. Guidance and repurchase announcement
• Positive Sentiment: The company authorized a $200 million share-repurchase program, which could support per-share results and signal confidence in its prospects. Share-buyback announcement
• Positive Sentiment: Wells Fargo raised its target to $37 and maintained an Overweight rating; Needham lifted its target to $38 and BTIG to $42, both with Buy ratings. Wells Fargo analyst rating
• Neutral Sentiment: Canaccord lowered its price target from $45 to $42 but kept a Buy rating. Reports also highlighted product innovation and market-share gains, though market volatility remains a factor. Product innovation and share gains

Analyst Upgrades and Downgrades

A number of analysts recently commented on ENOV shares. BTIG Research lifted their price target on Enovis from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday. Citizens Jmp decreased their target price on Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research report on Wednesday, September 2nd. Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Weiss Ratings raised shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 2nd. Finally, Canaccord Genuity Group dropped their target price on shares of Enovis from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Friday. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $38.62.

About Enovis

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.